Paris Descartes APHP and INSERM Poster # / Location: 4546 / Section 25, Board 1 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7648 The tumor inflammation
signature (TIS) and other
gene expression signatures, simultaneously
analyzed using the IO 360 panel, predict clinical benefit of anti-PD1 treatment (nivolumab and pembrolizumab) in «real life» patients with various cancer types, including NSCLC.